sively in the 8 states that do not guarantee $4 GDDP prices. Because we were characterizing cost sharing, beneficiary outof-pocket costs for each drug were determined for the first phase of coverage for each plan: the deductible phase for plans that required a deductible and offered coverage in this phase or the initial coverage zone.
Our primary outcomes were the proportion of plans requiring patients to spend more than $4 out of pocket to obtain a 30-day supply for covered medications and each drug's median out-of-pocket cost. Analyses were stratified by plan type (Medicare Advantage PDPs [MA-PDPs] vs. standalone PDPs) and tier category (tier 1 and select care tiers vs. all other tiers). Select care tiers have low beneficiary out-of-pocket costs, similar to those required for drugs in the preferred generic tier (tier 1), because Medicare assesses the adherence of each plan's beneficiaries to certain medications as part of the Five-Star Quality Rating System. Tier placement is independent of GDDP availability and determined solely by the PDP. Differences between plan types were analyzed using a MannWhitney U test. All analyses were performed using Stata, version 15.1 (StataCorp), and RStudio, version 1.1.423.
Our analysis involved 2155 Medicare PDPs, which comprised 1533 (71.1%) MA-PDPs and 622 (28.9%) standalone PDPs. From Walmart's GDDP list, we identified 27 generic medications used for prevalent CVD-related conditions; of these, Medicare PDPs covered a median of 25 medications (interquartile range [IQR], 25 to 27 medications). Across all medications and tiers, the median proportion of plans that required patients to spend more than $4 out of pocket for covered medications was 21.0% (IQR, 16.3% to 38.1%) (Figure) . The median total out-of-pocket cost of covered medications across all tiers was $2 (IQR, $0 to $5). These costs differed significantly between MA-PDPs and standalone PDPs for medications covered in tier 1 and select care tiers Discussion: A substantial proportion of Medicare PDPs in 2017 required patients to spend more out of pocket than Walmart's GDDP for 30-day supplies of 27 generic medications used to treat prevalent CVD-related conditions. In particular, MA-PDPs consistently required patients to spend more out of pocket than standalone PDPs, a counterintuitive finding considering that MA plans are responsible for acute care coverage, outpatient services, and other health care expenses for their beneficiaries and not solely pharmaceutical services like standalone PDPs.
Our study has important limitations. We do not know the number of beneficiaries enrolled in each plan or the generalizability of our findings to other drug classes. Enhancing information on out-of-pocket costs for PDPs, particularly comparing these costs with those for medications available through GDDPs, could decrease beneficiary drug spending. Efforts should include addressing laws that prohibit pharmacists from notifying patients about lower out-of-pocket prices for medications, especially given the widespread availability of GDDPs. Helping beneficiaries pay the lowest available price for generic medications may improve adherence among Medicare beneficiaries and, in turn, their clinical outcomes. 
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